Humana (HUM) Slid as Medicare Advantage Rate Fell Short of Expectations
Key takeaways
- A copy of the letter is available to download here.
- In its first-quarter 2026 investor letter, Artisan Value Fund highlighted stocks like Humana Inc.
- Artisan Value Fund stated the following regarding Humana Inc.
Humana (HUM) Slid as Medicare Advantage Rate Fell Short of Expectations Soumya Eswaran Tue, May 26, 2026 at 8:05 PM GMT+7 3 min read HUM Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for “Artisan Value Fund”. A copy of the letter is available to download here. The Funds’ Investor Class: ARTLX, Advisor Class: APDLX, and Institutional Class: APHLX returned -3.54%, -3.50%. and 3.50%, respectively, in Q1 vs, 2.10% return for the Russell 1000® Value Index. Performance was impacted by a market favoring momentum-driven stocks over quality factors, alongside company-specific setbacks. In Q1 2026, the US equity market showed mixed results: large-cap indices declined, while mid- and small-cap stocks gained modestly, reflecting a gradual broadening in market participation. Volatility increased, driven by concerns over artificial intelligence and private credit, and further escalated due to the outbreak of conflict in Iran. Despite uncertainty, the Fund focuses on identifying companies that can create value through cycles, particularly where market dislocations provide attractive entry points. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Artisan Value Fund highlighted stocks like Humana Inc. (NYSE:HUM). Humana Inc. (NYSE:HUM) is an American insurance company that provides medical and specialty insurance products. On May 22, 2026, Humana Inc. (NYSE:HUM) closed at $307.95 per share. One-month return of Humana Inc. (NYSE:HUM) was 37.71%, and its shares gained 36.91% over the past 52 weeks. Humana Inc. (NYSE:HUM) has a market capitalization of $36.97 billion.
Artisan Value Fund stated the following regarding Humana Inc. (NYSE:HUM) in its Q1 2026 investor letter: